Figures
Abstract
In chronic myelogenous (CML) and chronic eosinophilic leukemia (CEL), neoplastic cells spread via the circulation into various extramedullary organs. As E- and P-selectin constitute the starting point for the leucocyte adhesion/invasion cascade, and CEL and CML cells share many properties with normal granulocytes, we investigated the role of these selectins in CEL and CML cell expansion and organ invasion in a xenotransplantation model using scid mice. Using two human leukemic cell lines (EOL-1 and K562), we were able to show that E- and P-selectins mediate leukemia cell tethering and adherence in a laminar flow assay. While E-selectin binding depended on sialylated carbohydrate moieties, P-selectin binding was completely (K562) or partially (EOL-1) independent of these carbohydrates indicating the involvement of non-canonical selectin ligands. In a xenograft model in scid mice, both cell lines invaded the bone marrow and other organs, formed chloromas, and ultimately produced an overt leukemia. In contrast, in E- and P-selectin knockout scid mice, the cells failed to show engraftment in 8 out of 10 animals and even if they did engraft, they produced only little organ invasion and chloroma formation. Together, these data suggest that E- and P-selectins play an important role in leukemic dissemination in CML and CEL.
Citation: Wicklein D, Schmidt A, Labitzky V, Ullrich S, Valent P, Schumacher U (2013) E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model. PLoS ONE 8(7): e70139. https://doi.org/10.1371/journal.pone.0070139
Editor: Ken Mills, Queen’s University Belfast, United Kingdom
Received: May 29, 2013; Accepted: June 21, 2013; Published: July 26, 2013
Copyright: © 2013 Wicklein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The financial help of the Mildred Scheel Stiftung in providing the animal core facility is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Chronic myelogenous leukemia (CML) is a clonal hematopoietic neoplasm with an annual incidence of 1–2 per 100,000 comprising 5–10% of all cases of myeloid leukemias. In the chronic phase of CML, the malignant clone is largely dependent on BCR-ABL kinase activity [1], [2], [3], [4]. In line with this assumption, the disease can be successfully treated with BCR-ABL tyrosine kinase inhibitors (TKI) such as imatinib [5], [6]. However, many patients relapse after discontinuation of TKI therapy, even after having entered a complete molecular response [7], [8]. This phenomenon is best explained by resistance of leukemic stem cells (LSC) that are often quiescent cells and therefore cannot be all eliminated by TKI treatment [9], [10], [11]. These LSC reside in bone marrow stem cell niches where they occasionally enter the organ’s micro-circulation before being spread into the blood to enter new survival niches in the bone marrow and in various extramedullary organs [12], [13], [14].
Chronic Eosinophilic Leukemia (CEL) is a rare myeloproliferative neoplasm characterized by clonal expansion of eosinophils and typical organ damage [15], [16], [17], [18]. The neoplastic eosinophils in CEL often display PDGFRA fusion genes, resulting in constitutive tyrosine kinase activity [19], [20], [21]. Like CML, the disease can be successfully treated with imatinib [18], [22], [23].
Although CEL and CML LSC populate the entire bone marrow and also other vascularized organs over time, not much is known about the molecular mechanisms that are involved in the dissemination and homing processes underlying LSC dissemination through the blood stream in these leukemias.
Recent xenograft experiments indicated that E- and P-selectin play a major role in the metastatic cascade of colon and breast cancer [24], [25]. These studies suggest that cancer cells mimic the adhesion cascade of leukocytes to emigrate from the bloodstream in which they are unable to survive. As cancer cells use the same mechanisms as leukocytes do to leave the bloodstream, it seems obvious that leukemic cells which are malignant counterparts of normal leukocytes use the same mechanism to translocate from the circulation into tissues in various organs. Additionally, it was recently demonstrated that E-selectin is a crucial component of a hematopoietic stem cell (HSC) niche in the bone marrow, with E-selectin regulating HSC dormancy and self-renewal [26].
In the present study, we analyzed factors that may underlie the dissemination of CEL and CML cells during the dissemination step of disease evolution. As the leukocyte adhesion cascade is generally considered to start with the selectins [27] and E-selectin is part of a HSC niche which might be a potential LSC niche as well [26], we chose to use a recently established xenograft model of human CEL [28] to investigate the behavior of CEL and CML cells in E- and P-selectin deficient scid mice.
Materials and Methods
Cell Culture
The CEL cell line EOL-1, the CML cell line K562 (DSMZ, Braunschweig, Germany) and the control, pancreatic adenocarcinoma cell line PaCa 5061 (characterized in [29]) were cultured as previously described [28], [29].
Animal Experiments
The methodology for carrying out the animal experiments was consistent with the UKCCR guidelines for the welfare of animals in experimental neoplasia [30]. The experiment was recommended and supervised by the institutional animal welfare officer and approved by the local licensing authority (Behörde für Soziales, Familie, Gesundheit, Verbraucherschutz; Amt für Gesundheit und Verbraucherschutz; Billstr. 80, D-20539 Hamburg, Germany) under the project no. G10/55.
All animals used were pathogen-free Balb/c severe combined immunodeficient (scid) or E-selectin −/− and P-selectin −/− scid mice (previously described [24]) aged 9–14 weeks with a weight of 25–30 g at the beginning of the experiments. The mice were housed in filter-top cages, provided food and water ad libitum and their condition was monitored daily. Apart from visible chloroma and paraplegia, the general condition of the animals was evaluated by a standardized in house scoring system based on movement/behavior, weight development, food and water intake and fur condition. The mice were killed by cervical dislocation after having been anesthetized by intraperitoneal injection of a weight-adapted dose (10 µl/g bodyweight) of a mixture of 1.2 ml Ketamin (Gräub AG, Bern, Switzerland), 0.8 ml Rompun (Bayer AG, Leverkusen, Germany) and 8 ml saline.
Flow Cytometry
Unconjugated antibodies against sialyl Lewis a/CA19-9 (Abcam), Cutaneous Lymphocyte Antigen (HECA-452), sialyl Lewis x/CD15s (CSLEX1) BD Biosciences, Heidelberg, Germany) and corresponding mouse IgM or rat IgM isotype control, respectively (Dako, Glostrup, Denmark), were detected with allophycocyanin (APC) conjugated goat anti-mouse Ig (BD Biosciences).
Cells were analyzed using a FACSCalibur cytometer (BD Biosciences). For assessment of E- and P-selectin binding on human tumor cells, E- and P-selectin chimeric proteins (R&D, Wiesbaden, Germany) were complexed by incubation with goat anti-human IgG1-biotin (Sigma Aldrich, Hamburg, Germany) and subsequent addition of phycoerythrin (PE, Dako) or APC (BD) conjugated streptavidin before staining.
Neuraminidase treatment experiments were performed by incubating the cells in PBS with or without 10 mU Neuraminidase from C. perfringens (Roche Diagnostics, Mannheim, Germany) for 1 h at 37°C prior to staining.
Laminar Flow Adhesion Assay
Laminar flow experiments were performed as previously described [31]. Applied shear rates were 0.25 dyn/cm2 and 0.5 dyn/cm2.
Xenograft Mouse Model of Human CEL and CML using EOL-1 Cells and K562 Cells
The experiment was carried out with 10 scid and 10 E-selectin −/−, P-selectin −/− scid mice in each group. For injection, EOL-1 cells or K562 cells were washed and resuspended in saline at 2×107 cells per ml. All mice received an intravenous injection of 2×106 EOL-1 or K562 cells (in 100 µl saline), respectively. The animals were controlled for development of symptoms of leukemia and/or visible chloroma each day. Mice with severe symptoms (in most cases apathy or paraplegia) were euthanized immediately.
Immunohistochemistry
Immunohistochemistry using sections of paraffin-embedded tissues was carried out as previously described [28], [32].
DNA Extraction and Real-time PCR for Detection of Human Leukemic Cells
DNA extraction from murine blood and quantification of human leukemia cells by real-time polymerase chain reaction (PCR) were performed as previously described [33]. For the quantification of human leukemia cells from bone marrow, 60 ng of DNA isolated from the animals’ bone marrow were used as template.
Statistical Analyses
Statistical Analyses (Log-rank tests for the Kaplan Meier survival curves and Mann Whitney tests for leukemia cell numbers in blood and bone marrow) were performed using GraphPad Prism 5 (GraphPad, La Jolla, CA, USA). Tests used are given for each P value in the results section. Results were considered statistically different when the P value was below 0.05.
Results
Selectins Bind to Human CEL and CML Cells
Binding of human E- and P-selectin to the human cell lines EOL-1 and K562 was investigated by flow cytometry. EOL-1 cells were found to bind to human E-selectin (Figure 1A) and human P-selectin (Figure 1B). K562 cells displayed weak human E-selectin binding (Figure 1C) and moderate human P-selectin binding (Figure 1D).
Binding of human E- and P-selectin to human CEL and CML cells was analyzed by flow cytometry. Given in the histograms are the fluorescence signal (FL-1 for AlexaFluor488 or FL-2 for phycoerythrin) and event number, selectin binding is represented by the filled curves, controls by the open curves. Cell lines and selectins used were: EOL-1 and human E-selectin (A), EOL-1 and human P-selectin (B), K562 and human E-selectin (C) and K562 and human P-selectin (D). All experiments were repeated twice, representative results are shown.
To investigate whether E- and P-selectin mediate tethering or adherence of human CEL and CML cells under shear stress (more closely reflecting in vivo conditions than the static incubation in the flow cytometry experiments), laminar flow adhesion experiments with both cells lines, EOL-1 and K562, were performed. Flow channels were coated with human and murine selectins, respectively.
Both cell lines showed only weak adhesion to human and murine P-selectin. K562 cells displayed a similarly weak adhesion to both human and murine E-selectin (Figure 2A), while EOL-1 cells showed a stronger adhesion to human and murine E-selectin than the K562 cells.
Interactions of human CEL and CML cells from culture under laminar flow (0.25 dyn/cm2) in selectin coated channels. The cell lines EOL-1 and K562 were tested for adherence (A) or tethering (B). Given are the numbers and corresponding standard deviations of adhering and tethering cells, respectively. Channels were coated with human E-selectin (E), human P-selectin (P), murine E-selectin (mE) or murine P-selectin (mP). No adhering or tethering cells were observed in Fc control coated channels. All experiments were done in triplicates.
Both cell lines showed only weak tethering in (human and murine) P-selectin coated channels. Almost no tethering EOL-1 cells were observed in channels coated with human or murine E-selectin, whereas K562 cells displayed strong tethering on human and murine E-selectin (Figure 2B).
Selectins are Essential in Leukemia Cell Engraftment in a Xenograft Model of Human CEL with EOL-1 Cells
Two wt mice injected with EOL-1 cells were found dead one day after injection and were excluded from further analyses. All remaining wt animals injected with EOL-1 cells developed varying symptoms of eosinophilic CEL, i.e. cachexia, apathy, palpable tumors/chloroma (Figure 3A) and/or paraplegia, and had to be euthanized after 26 to 34 days (median 32 days, Figure 4A). This part of the experiment was therefore terminated after 53 days. One mouse of the corresponding k.o. group had to be euthanized after 32 days due to paraplegia (without any further signs of CEL). The animal showed 1605 EOL-1 cells/ml blood, however, necropsy revealed no signs of chloromas and no EOL-1 cells were found in histology. On day 53 only one animal of the k.o. group showed a palpable subcutaneous tumor on the back, but displayed no further signs of CEL and, correspondingly, no median survival can be given for the k.o. group (Figure 4A). The resulting survival curves of the wt and k.o. animals for EOL-1 were significantly different (P<0.0001, Log-rank test).
A: Tissue section of an EOL-1 chloroma of selectin wt scid mouse. Immunohistochemical staining for human HLA-DR in red. B: Tissue section of a K562 chloroma of a wt scid mouse. Immunohistochemical staining for human mitochondria in red.
Selectin deficiency dramatically increases survival of the animals after injection of 2×106 EOL-1 cells and decreases the number of leukemia cells in the blood. A: Kaplan-Meyer survival curve for wild-type (wt, selectin competent, 8 animals, grey curve) and selectin knockout (k.o., E-and P-selectin deficient, 10 animals, black curve). The percentage of surviving animals on a given day is shown. The experiment was terminated after 53 days. Median survival after transplantation was: wt 32 days, k.o. not reached. The curves were significantly different, ***: P<0.0001 (Log-rank test). B: Human EOL-1 cells in the animals’ blood at the time of death as determined by quantitative real-time PCR. Selectin competent (wt, 8 animals) are compared with E- and P-selectin deficient mice (k.o., 9 animals). Given in the box plot are the median (line), highest and lowest number of EOL-1 cells per ml of the animals’ blood (whiskers) and upper and lower quartile (box). Median cell number per ml blood was 32950 for the wt group and 7.8 for the k.o. group. The difference between the groups was significantly different, ***: P = 0.0002 (Mann Whitney test).
Necropsy and histology revealed multiple organ involvement in the wt group: various animals developed solid chloromas located at the spine (animals showed corresponding paraplegia), in the peritoneum and/or the thorax and showed infiltrations of EOl-1 cells in the bone marrow, liver and/or lung. In the k.o. group, only three animals developed small chloromas in the thorax and only two of these mice showed infiltrations of EOl-1 cells in the liver. No further infiltrations by EOL-1 cells were found in any of the other animals of the k.o. group. Quantitative real time PCR (qRT-PCR) showed a significantly reduced number of EOL-1 cells in the k.o. animals’ blood at the time of death (median of 7.8 EOL-1 cells/ml blood in the k.o. group, range 0 to 2210 cells/ml) compared with the wt group (median of 32950 EOL-1 cells/ml blood, range 1895 to 3.41×106 cells/ml); P<0.0001, Mann Whitney test; (Figure 4B).
Summarized, injection of EOL-1 cells caused massive organ infiltration by leukemia cells, chloroma development and massive presence of EOL-1 cells in the animals’ blood in the selectin competent mice. In contrast, small chloromas developed in 30% of the selectin deficient animals, organ infiltration (only liver) was observed in 20% of the selectin deficient mice and only few leukemia cells were detected in their blood. These data suggest an essential effect of the selectins on CEL cell engraftment.
Selectins are Essential in Leukemia Cell Engraftment in a Xenograft Model of Human CML with K562 Cells
In mice xenografted with K562 cells, 8 out of 10 animals of the wt group had to be euthanized at some time point during the experiment (it was terminated after 56 days, Figure 5A). All of these animals had developed varying symptoms of CML, i.e. cachexia, apathy, palpable tumors/chloromas (Figure 3B). In these mice, no paraplegia was observed. Using qRT-PCR, varying amounts of K562 cells were found in these animals’ blood and in the bone marrow of all mice but one. Additionally, six of these animals showed visible facial tumors/chloromas. Two mice had not developed any symptoms until day 56 and both animals did not show any chloromas although a low amount (14.5 cells/ml) of K562 cells was detected in the blood of one of the two mice by qRT-PCR. Additionally, K562 cells were found in this animal’s lung using immunohistochemistry. Thus, only one animal (10%) of the wt group showed no signs of engraftment until the end of the experiment.
Selectin deficiency dramatically increases survival of the animals after injection of 2×106 K562 cells and decreases the number of leukemia cells in blood and bone marrow. A: Kaplan-Meyer survival curve for wild-type (wt, selectin competent, 10 animals, grey curve) and selectin knockout (k.o., E-and P-selectin deficient, 10 animals, black curve). The experiment was ended after 56 days. Median survival after transplantation was: wt 48.5 days, k.o. not reached. The curves were significantly different, **: P = 0.0085 (Log-rank test). B: Human K562 CML cells (given in cells/ml) in the animals’ blood at the time of death as determined by quantitative real-time PCR (qRT-PCR). Selectin competent (wt, n = 10) compared with E- and P-selectin deficient mice (k.o., n = 10). Given in the box plot are the median (line), highest and lowest number of K562 cells per ml of the animals’ blood (whiskers) and upper and lower quartile (box). Median cell number per ml blood was 268.8 for the wt group and 0.2 for the k.o. group. The difference between the groups was significantly different, **: P = 0.0068 (Mann Whitney test). C: Human K562 CML cells in the animals’ bone marrow at the time of death as determined by qRT-PCR (given in cells/60 ng template DNA). Given in the box plot are the median (line), highest and lowest number of K562 cells (whiskers) and upper and lower quartile (box). Median cells per 60 ng template DNA in the wt group were 243 compared with 0 cells in the k.o. group. This difference was significant, **: P = 0.0089 (Mann Whitney test).
In the selectin k.o. group, only two animals developed symptoms of CML until day 56 and had to be euthanized (Figure 5A). These two mice were the only ones in this group that displayed facial tumors and other chloromas and were qRT-PCR positive for K562 cells in blood and bone marrow.
Summarized, qRT-PCR results were: Median of 268.8 cells/ml blood (range 0 to 28657 cells) in the wt group compared with a median of 0.2 in the k.o. group (range 0 to 7237 cells) (Figure 5B). This difference was significant (P = 0.0068, Mann Whitney test). In the bone marrow of the wt mice, a median of 243 cells/60 ng template DNA was detected (range 0 to 122047 cells) compared with a median of 0 cells/60 ng template DNA (range 0 to 5112 cells) in the selectin k.o. group (Figure 5C). Again, this difference was significant (P = 0.0089, Mann Whitney test).
Injection of K562 cells caused massive organ infiltration by leukemic cells, chloroma development and presence of K562 cells in the blood of 90% of the animals in the selectin competent mice. In the selectin deficient animals, only 20% of these mice developed chloromas and showed signs of bone marrow infiltration and only very few leukemic cells were detected in their blood. No further infiltration of other organs was observed in any of the selectin deficient animals. These data suggest an essential effect of the selectins on CML cell engraftment.
Detection of Selectin Ligands on CEL and CML Cell Lines
In order to identify the E- and P-selectin ligands on cells of the human CEL and CML cell lines, selectin binding after (pre)incubation of cells from culture with potentially inhibiting antibodies was measured by flow cytometry. The selectin binding human pancreatic carcinoma cell line PaCa 5061 was used as a positive control [34].
Of the described selectin ligands, EOL-1 cells displayed only a small subpopulation of sialyl Lewis a (CA19-9) positive cells (3.7%), but were highly positive for sialyl Lewis × (CD15s), whereas K562 cells were negative for both (Figure 6). Both cells lines were positive for CD162 (PSGL-1).
Only EOL-1 cells are positive for sialyl Lewis x, both cell lines are positive for CD162 (PSGL-1). Cells were incubated with antibodies against CA19-9 (sialyl lewis a), CD15s (sialyl lewis x) or CD162 (PSGL-1) or the respective isotype controls followed by an APC-labelled secondary antibody. Given in the histograms are the fluorescence signals and event numbers, labeling with the antibodies against selectin ligands is represented by the filled curves, the respective isotype controls by the open curves. Only a small subpopulation (3.7%) of EOL-1 cells was positive for CA19-9. The cells were either completely negative or more than 95% positive for the other ligands. All experiments were repeated twice, representative results are shown.
Antibodies against sialyl Lewis x (CD15s, Figure 7A) and sialyl Lewis a (CA19-9, Figure 7B) did not inhibit E- and P-selectin binding to EOL-1 and K562 cells although anti-CA19-9 (and not anti-CD15s) did completely block E-selectin binding to PaCa 5061 cells as previously described [34]. Even the monoclonal antibody HECA-452 which has a broader specificity (CA19-9 and CD15s among other carbohydrate moieties) had no inhibitory effect on E- and P-selectin binding to the CEL and CML cells, but blocked E-selectin binding to PaCa 5061 cells (not shown). An antibody against CD162 (PSGL-1) blocked P-selectin binding to EOL-1, but not to K562 (Figure 7A), whereas E-selectin binding to both cell lines was not influenced by anti-CD162 (not shown).
A: Blocking of P-selectin binding by (pre)incubation with monoclonal antibodies against CD15s and CD162. Filled curves in the histograms represent incubation of the leukemia cells with isotype control, open curves represent incubation with the respective specific antibody. The only observed inhibitory effect was caused by anti-CD162 on EOL-1, but not on K562 cells. B: Blocking of E-selectin binding by (pre)incubation with monoclonal antibodies against CA19-9. Filled curves in the histograms represent incubation of the cells with isotype control, open curves represent incubation with the specific antibody. The only observed inhibitory effect by anti-CA19-9 was observed on PaCa 5061 pancreatic adenocarcinoma cells (positive control). C: Binding of selectins to the leukemia cells after neuraminidase treatment. Filled curves in the histograms: selectin binding without neuraminidase incubation (positive control); open curves, black: selectin binding to neuraminidase treated cells; open curves, grey: negative controls. Neuraminidase treatment abolished E-selectin binding to both cell lines and reduced P-selectin binding to EOL-1 but not to K562 cells. All experiments were repeated twice, representative results are shown.
As we were unable to confirm that the described selectin ligands sialyl Lewis a and sialyl Lewis x played any role in selectin binding to the CEL or CML line used in our experiments, we treated the cells with neuraminidase (sialidase) to investigate whether sialylated carbohydrate moieties were involved in selectin binding at all. Treatment with neuraminidase abolished E-selectin binding to both EOL-1 and K562 cells and considerably reduced P-selectin binding to EOL-1 cells. However, P-selectin binding to K562 cells was not affected by neuraminidase digestion (Figure 7C).
Discussion
This study was undertaken to analyze the functional role of E- and P-selectin in the process of leukemic dissemination in CML and CEL. Both cell lines used bound to E- and P-selectin fusion proteins: This binding was more intense in EOL-1 cells (moderate to E- and strong to P-selectin) compared to K562 (weak to E- and moderate to P-selectin) and interacted with the selectins under laminar flow conditions. The pathophysiological role of selectin binding could be verified in vivo: E- and P-selectin deficient mice showed dramatically increased survival and little organ infiltration and chloroma formation were observed compared with wt mice. Additionally, there were only few to no circulating leukemia cells in the selectin deficient animals’ blood. These observations indicate that E- and P-selectin play an important role in organ infiltration and chloroma formation by CEL and CML cells. Flow cytometric analysis in earlier xenograft experiments with EOL-1 cells showed that nearly all cells vanish from the murine bloodstream after intravenous injection and reappear in the blood about 28 days later [28]. Thus, the human leukemia cells obviously left the bloodstream to home into at least one type of survival niche in the murine organism (in the bone marrow and/or other organs). Whether this niche is similar or identical to the Leukemia Stem Cell (LSC) niche [35], [36] and whether the leukemia cells can establish LSCs in the animals, is a highly pertinent question that can be studied in vivo in this model. However, it should be stated that the model applied here employed human cell lines and that cell line-specific LSC may differ from primary LSC in patients regarding their biology and expansion.
Obviously, the leukemia cells were unable to survive in the bloodstream for extended periods of time: In the selectin k.o. animals where the leukemia cells’ ability to leave the bloodstream and enter the organs was impaired, only a minority of the mice showed any sign of tumor cell engraftment at all. This might imply a dynamic situation in human patients as well, with leukemia cells that may constantly be redistributed from and into the bone marrow (and probably also other organs) and adhesion receptors such as E- and P-selectin may play an important role in this redistribution process. Thus, the selectins might be involved in the spread of LSC to new sites in the bone marrow and other organs. Recently, it has been suggested that LSC in acute myelogenous leukemia use the circulation to reach these new sites where they utilize selectins, integrins and other molecules of the leukocyte cascade to leave the bloodstream and subsequently enter their niche again [14]. For hematopoietic stem cells (HSCs) at least two survival niches exist in the bone marrow, as the HSCs are either associated with sinusoidal endothelium or endosteum [37]. Recently, it was demonstrated, that E-selectin is part of the sinusoidal endothelial survival niche itself and that the selectin regulates dormancy and self-renewal of HSCs [26]. If these findings also apply to the survival niche(s) of the EOL-1 and K562 leukemia cells, the selectin deficiency could have effects on both niches: The injected leukemia cells would have a drastically reduced probability of reaching the endosteal survival niche as their ability to leave the bloodstream (adherence to and crossing of the endothelium) is impaired. In the sinusoidal endothelial niche, the lack of E-selectin might prevent the leukemia cells from self-renewal/proliferation. As a result of these two effects, the overall number of leukemia cells in the animals’ bone marrow and blood could have dropped below the detection threshold. Due to the selectin deficiency, the few leukemia cells escaping dormancy in the endothelial niche of the k.o. mice would again encounter great difficulties leaving the bloodstream to invade organs or establish chloromas. Future experiments will have to answer the question if (and then to what extent) a dormancy effect similar to the one described for HSCs [26] is involved in the effects of selectin deficiency in our xenograft model.
With the exception of CD162, we were not able to identify the E- and P-selectin ligands on the surface of the leukemia cell lines used in our experiments by inhibition with monclonal antibodies specific for published selectin ligands. Only an anti-CD162 (PSGL-1) antibody inhibited P-selectin binding to EOL-1, but not to K562 cells. Surprisingly, antibodies specific for sialyl Lewis a (CA19-9) and sialyl Lewis x (CSLEX1) and the antibody HECA-452 (recognizing both carbohydrate moieties) were unable to inhibit E- or P-selectin binding to EOL-1 and K562 cells (which had to be expected in the latter case as K562 cells are negative for sialyl Lewis a and x). In contrast, the antibody against sialyl Lewis a inhibited E-selectin binding to the pancreatic adenocarcinoma cell line PaCa 5061 (used as positive control), as described earlier [34]. It has been known for decades that the presence of sialyl Lewis x alone is not sufficient for a protein to function as a selectin ligand [38] and it has been shown recently that binding of HECA-452 does not block simultaneous E-selectin binding to sialyl Lewis x microspheres [39]. Our results appear to verify the latter finding on a cellular level. It is unlikely, however, that the antibody (CSLEX1) against sialyl Lewis x that we used in this study is similar to HECA-452 in this respect (not able to block simultaneous selectin binding) as it has been shown to block E- and P-selectin binding on a cellular level before [40], [41]. We could show that sialylated carbohydrate moieties are involved in E-selectin binding to EOL-1 and K562 cells, as neuraminidase (sialidase) digestion abolished E-selectin binding to both cell lines. Interestingly, neuraminidase digestion only partially inhibited P-selectin binding to EOL-1, but not to K562 cells where P-selectin binding was unaltered by neuraminidase digestion, indicating that P-selectin binding does not depend on neuraminic acid in the latter case. Other carbohydrate moieties might be critically involved in selectin binding to the leukemia cells, as especially indicated by the results for K562 cells and P-selectin. Taken together, our results suggest that the selectins mainly bind to noncanonical ligands on the CEL and CML cells. Interestingly, it has been shown recently, that binding of HSCs to E-selectin is also mediated by noncanonical selectin ligands [26]. If the EOL-1 and K562 cells display the same (hitherto unidentified new E-selectin ligands) this would give further credit to the assumption that the absence of E-selectin from the endothelial survival niche causes a dormancy effect similar to the HSCs. Taking into consideration that in CEL and CML cell lines the situation with E- and especially P-selectin ligands appears to be more complicated than expected from recent literature on granulocytes – which more or less takes the essential role of sialyl Lewis x for granted [42], [43] – we think that our results certainly warrant further examination of the selectin ligands on other cell lines of CEL, CML and other leukemia entities as well. As leukemia cells display surface expression of markers typical for their normal leukocyte counterparts (e.g. B-lymphoid CLL cells CD19, CD20 etc.) it is more than likely that they express selectin ligands as well [12]. Further experiments will have to include different types of leukocytes to clarify if differences in carbohydrate involvement in E- and P-selectin binding reflect the different progenitor cells of the leukemia cell lines (e.g. eosinophilic granulocyte or monocyte precursors). It will also be essential to know whether primary leukemic stem cells (LSC) derived from patients with CML and CEL express selectin ligands and invade tissues in a selectin-specific manner. Notably, it is well known that LSC in CML interact with several types of niches in various organs, and that LSC-niche interactions contribute to self-renewal and drug resistance [10], [36]. Finally, it is generally appreciated that LSC are important targets of therapy in various types of acute and chronic leukemia [44], [45], [46], [47].
Acknowledgments
We would like to thank Susanne Feldhaus, Christine Knies and Carsten Köpke for excellent technical assistance and Nuno Ramos Leal and Johannes Salamon for technical advice on i.v. injections.
Author Contributions
Conceived and designed the experiments: DW AS SU PV US. Performed the experiments: DW AS VL. Analyzed the data: DW AS VL SU PV US. Contributed reagents/materials/analysis tools: SU PV US. Wrote the paper: DW AS PV US.
References
- 1. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550–554.
- 2. Goldman JM, Melo JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1084–1086.
- 3. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441–453.
- 4. Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1: 31–36.
- 5. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004.
- 6. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417.
- 7. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029–1035.
- 8. Cortes J, O’Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204–2205.
- 9. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107: 4532–4539.
- 10. Valent P (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 142: 361–378.
- 11. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, et al. (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926–935.
- 12. Krause DS, Van Etten RA (2007) Right on target: eradicating leukemic stem cells. Trends Mol Med 13: 470–481.
- 13. Crews LA, Jamieson CH (2012) Chronic myeloid leukemia stem cell biology. Curr Hematol Malig Rep 7: 125–132.
- 14. Liesveld J (2012) Targeting myelogenous leukemia stem cells: role of the circulation. Front Oncol 2: 86.
- 15. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, et al. (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18: 734–742.
- 16. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C (2008) The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 87: 1–10.
- 17. Gotlib J, Cross NC, Gilliland DG (2006) Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19: 535–569.
- 18. Valent P (2009) Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 23: 157–165.
- 19. Ishihara K, Kitamura H, Hiraizumi K, Kaneko M, Takahashi A, et al. (2008) Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. Biochem Biophys Res Commun 366: 1007–1011.
- 20. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, et al. (2010) Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 126: 45–49.
- 21. Gotlib J, Cools J (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22: 1999–2010.
- 22. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.
- 23. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, et al. (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143: 707–715.
- 24. Köhler S, Ullrich S, Richter U, Schumacher U (2009) E−/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer 102: 602–609.
- 25. Stübke K, Wicklein D, Herich L, Schumacher U, Nehmann N (2012) Selectin-deficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett 321: 89–99.
- 26. Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, et al. (2012) Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med 18: 1651–1657.
- 27. Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678–689.
- 28. Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, et al. (2012) Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One 7: e30567.
- 29. Kalinina T, Gungor C, Thieltges S, Moller-Krull M, Penas EM, et al. (2010) Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer 10: 295.
- 30. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555–1577.
- 31. Richter U, Schroder C, Wicklein D, Lange T, Geleff S, et al. (2011) Adhesion of small cell lung cancer cells to E- and P-selectin under physiological flow conditions: implications for metastasis formation. Histochem Cell Biol 135: 499–512.
- 32. Thies A, Mauer S, Fodstad O, Schumacher U (2007) Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br J Cancer 96: 609–616.
- 33. Nehmann N, Wicklein D, Schumacher U, Muller R (2009) Comparison of two techniques for the screening of human tumor cells in mouse blood: quantitative real-time polymerase chain reaction (qRT-PCR) versus laser scanning cytometry (LSC). Acta Histochem 112: 489–496.
- 34.
Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, et al.. (2012) Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp−/rag2– mice. Gut.
- 35. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466: 829–834.
- 36. Lane SW, Scadden DT, Gilliland DG (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114: 1150–1157.
- 37. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109–1121.
- 38. Varki A (1997) Selectin ligands: will the real ones please stand up? J Clin Invest 99: 158–162.
- 39. Kummitha CM, Shirure VS, Delgadillo LF, Deosarkar SP, Tees DF, et al. (2012) HECA-452 is a non-function blocking antibody for isolated sialyl Lewis x adhesion to endothelial expressed E-selectin under flow conditions. J Immunol Methods 384: 43–50.
- 40. Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, et al. (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250: 1130–1132.
- 41. Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, et al. (1991) CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x. Proc Natl Acad Sci U S A 88: 6224–6228.
- 42. Zarbock A, Ley K, McEver RP, Hidalgo A (2011) Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 118: 6743–6751.
- 43. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS (2007) Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 26: 477–489.
- 44. Valent P (2011) Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 11: 56–71.
- 45. Konopleva M, Tabe Y, Zeng Z, Andreeff M (2009) Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 12: 103–113.
- 46. Essers MA, Trumpp A (2010) Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 4: 443–450.
- 47. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12: 767–775.